Tadalafil Tablet, Film Coated
Product Images NDC 82968-002

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 82968-002). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fourrts (india) Laboratories Private Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tadalafil Tablet Usp 10mg (NDC)

Label for Tadalafil Tablets, USP 10 mg, film-coated oral tablets. The label indicates a package of 30 tablets manufactured by Fourrts (India) Laboratories Pvt. Ltd. and distributed by Fourrts Pharmaceuticals USA LLC. It includes dosage and storage instructions along with a barcode and manufacturing details.*

FDA Label Image

Tadalafil Tablet Usp 20mg (NDC)

Tadalafil Tablets USP 20 mg film-coated tablets label displaying the product strength prominently. The label states it contains 30 tablets and includes manufacturer Fourrts (India) Laboratories Pvt. Ltd., Chennai, India, and distributor Fourrts Pharmaceuticals USA LLC, Park Ridge, NJ. It includes usage instructions to not split tablets and storage information, along with a barcode on the right side.*

FDA Label Image

Tadalafil Tablet Usp 5mg (NDC)

Tadalafil Tablets, USP 5 mg film-coated tablets packaging label from Fourrts (India) Laboratories Pvt. Ltd. The label indicates 30 tablets per package with storage instructions, usage warnings, and manufacturer and distributor details. The label also includes dosage caution and a barcode.*

FDA Label Image

Tadalafil Tablet Usp 2.5mg (NDC 82968-001-03- 15s-Blister Label)

Sheet of Tadalafil Tablet USP labels, each indicating 2.5 mg strength. The labels specify Rx only, manufactured by Fourrts Pvt. Ltd., Chennai, India with space for batch number and expiration date. Each label includes a barcode for scanning.*

FDA Label Image

Tadalafil Tablet Usp 5mg (NDC)

Sheet of multiple Tadalafil Tablet, USP 5 mg film-coated tablet labels. Each label is rectangular with text showing the product name, strength, prescription only status, manufacturer Fourrts Pvt. Ltd. Chennai, India, along with placeholders for batch number and expiration date, plus a barcode on the right side. The labels are arranged in three columns and five rows.*

FDA Label Image

Tadalafil Tablet Usp 2.5mg (NDC 82968-001-03- 30s-carton Label)

Tadalafil Tablets, USP 2.5 mg per tablet film-coated tablets carton label for once daily use. The package contains 30 tablets (2 cards of 15 tablets) with each tablet containing 2.5 mg tadalafil. Manufactured by Fourrts (India) Laboratories Pvt. Ltd. and distributed by Fourrts Pharmaceuticals USA LLC. Includes dosage instructions and storage information.*

FDA Label Image

Tadalafil Tablet Usp 5mg (NDC)

Packaging label for Tadalafil Tablets, USP 5 mg film-coated tablets for oral use. The carton contains 30 tablets (2 cards of 15 tablets) with each tablet containing 5 mg tadalafil, intended for once daily use. The label lists Fourrts (India) Laboratories Private Limited as the manufacturer and Fourrts Pharmaceuticals USA LLC as the distributor.*

FDA Label Image

Chemical Structure (Tadalafil F001 Structure)

Chemical structure diagram of Tadalafil, showing its molecular arrangement with multiple ring systems and functional groups characteristic of the active ingredient.*

FDA Label Image

Figure (Tadalafil F001)

A set of four line graphs illustrating the difference in blood pressure (systolic and diastolic) between Tadalafil and placebo over time (0 to 96 hours). The graphs show standing systolic and diastolic BP on the top row and supine systolic and diastolic BP on the bottom row, with values plotted as difference in mmHg against time in hours.*

FDA Label Image

Figure (Tadalafil F002)

Two line charts showing changes in systolic blood pressure over 24 hours post-dose. The top chart displays standing systolic blood pressure, and the bottom chart shows supine systolic blood pressure. Both charts compare Tadalafil 20 mg with doxazosin 8 mg (solid line) versus placebo with doxazosin 8 mg (dotted line). The x-axis represents time in hours post-dose, and the y-axis measures blood pressure change in mmHg.*

FDA Label Image

Figure (Tadalafil F003)

A line graph showing systolic blood pressure (mmHg) changes over time after administration of tadalafil or placebo with doxazosin. The x-axis represents time in hours after drug administration, and the y-axis shows systolic blood pressure changes. Four lines compare 20 mg tadalafil at 08:00 and 20:00 doses with placebo, both combined with 8 mg once-daily doxazosin.*

FDA Label Image

Figure 4 (Tadalafil F004)

A line graph depicting plasma tadalafil concentration (µg/L) against time (hours) for different tadalafil dosing regimens. It compares single doses of 20 mg and 5 mg tadalafil and a once-daily 5 mg tadalafil dose after 5 consecutive days, illustrating concentration changes over a span of 120 hours with error bars shown for variability.*

FDA Label Image

Figure 5 (Tadalafil F005)

A line graph depicting the change from baseline in IPSS total score over a 12-week treatment period, comparing Tadalafil 5 mg tablets to placebo. The x-axis shows duration of treatment in weeks, and the y-axis shows change in score, illustrating greater score reduction with Tadalafil than placebo over time. Statistical significance is noted at p<0.01.*

FDA Label Image

Figure 6 (Tadalafil F006)

A line chart comparing the change from baseline in IPSS total score over 12 weeks of treatment with Tadalafil 5 mg versus placebo. The x-axis shows treatment duration in weeks, and the y-axis shows change in score. The chart indicates a greater decrease in score for Tadalafil versus placebo, with statistical significance noted.*

FDA Label Image

Figure 7 (Tadalafil F007)

A line graph depicting the least-squares mean change from baseline over weeks of therapy (0, 4, 12, 26) comparing Tadalafil/Finasteride and Placebo/Finasteride treatments. Data points are marked with symbols for each treatment group, showing greater decrease for Tadalafil/Finasteride, with p-values indicating statistical significance.*

FDA Label Image

Figure 8 (Tadalafil F008)

A line graph depicting changes from baseline in IIEF-5 total score over treatment duration in weeks, comparing Tadalafil 5 mg to placebo. The x-axis represents treatment duration in weeks; the y-axis shows change from baseline in IIEF-5 score. Two lines illustrate score changes for Tadalafil 5 mg and placebo groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.